logo
Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

Globe and Mail10-06-2025
OSAKA, Japan , /CNW/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in Japan , the company has grown from a small team with a bold vision into a global organization supporting clinical trials in more than 30 countries.
From the beginning, Linical set out to do more than manage clinical studies — the company set out to make a meaningful impact on patients' lives. Over the years, Linical's services have expanded to include full-service clinical trial management, site selection and feasibility, regulatory support, biometrics, pharmacovigilance, and drug development strategies. Throughout this growth, Linical's core mission has remained the same: to advance science while prioritizing patient safety and wellbeing.
"What began as a small startup with a few dedicated professionals from the pharmaceutical industry has grown into a global force in clinical research," said Kazuhiro Hatano , President and CEO of Linical. "We've never lost sight of the fact that at the heart of every clinical trial is a patient who is hoping for a better future. That's what continues to drive us."
Over the past two decades, Linical has supported hundreds of clinical studies across a range of therapeutic areas including oncology, neurology, immunology, and rare diseases. By leveraging technology and data-driven processes, the company has delivered faster study start-up times, improved site performance, and enhanced trial quality. Its investments in decentralized trial capabilities and digital tools have positioned the company at the forefront of innovation, especially in an era where flexibility and accessibility in research are more critical than ever.
The company attributes its success to a collaborative culture, strong partnerships with sponsors and sites, and an unwavering focus on patients. "Clinical research is ultimately about people," added Mr. Hatano. "It's about the people participating in trials, the investigators treating them, and the sponsors developing new therapies. We're proud to be part of that ecosystem, helping turn scientific discovery into real-world impact."
As it marks its 20th year, Linical is also looking ahead. The arrival of artificial intelligence is transforming the clinical research industry. With continued investment in global operations, advanced analytics, and patient-focused technologies, the company plans to further strengthen its ability to deliver efficient, high-quality clinical trials that bring new treatments to market faster.
"We're proud of what we've achieved, but we're even more excited about the future," said Mr. Hatano. "Our work is far from done, and we remain committed to our purpose: improving lives through research."
About Linical:
Linical is a global provider of clinical research services, supporting biopharmaceutical companies in bringing innovative therapies to patients across APAC, Europe , and North America . With a focus on quality, technology, and patient wellbeing, Linical delivers tailored solutions for clinical trials across all phases and numerous therapeutic areas.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

Globe and Mail

timea day ago

  • Globe and Mail

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.

Pfizer's PAXLOVID Study: Real-World Insights on COVID-19 Treatment
Pfizer's PAXLOVID Study: Real-World Insights on COVID-19 Treatment

Globe and Mail

time2 days ago

  • Globe and Mail

Pfizer's PAXLOVID Study: Real-World Insights on COVID-19 Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting a study titled 'Post Marketing Surveillance to Observe Safety and Effectiveness of PAXLOVID in Patients With Positive Results of Viral Testing, and Who Are at High Risk for Progression to Severe COVID-19.' The study aims to assess the real-world safety and effectiveness of PAXLOVID in patients at high risk of severe COVID-19, particularly in Korea. This is significant as it provides insights into the drug's performance outside controlled clinical settings. The intervention being tested is PAXLOVID, an antiviral treatment intended to reduce the severity of COVID-19 in high-risk patients. The study focuses on patients who have tested positive for the virus and are at risk of severe outcomes, including hospitalization or death. This observational study follows a case-only model and does not involve any specific allocation or masking. The primary purpose is to gather real-world data on PAXLOVID's effectiveness and safety over a 28-day follow-up period after treatment. The study began on November 29, 2023, with its primary completion and estimated study completion dates yet to be announced. The last update was submitted on July 22, 2025, highlighting ongoing data collection and analysis. Market implications of this study are significant for Pfizer's stock performance as positive real-world data could bolster investor confidence and market position against competitors. The study's outcomes may influence healthcare providers' decisions and potentially increase PAXLOVID's market share. The study is currently recruiting, with further details available on the ClinicalTrials portal.

AstraZeneca's Innovative Cancer Study: A Potential Game-Changer?
AstraZeneca's Innovative Cancer Study: A Potential Game-Changer?

Globe and Mail

time2 days ago

  • Globe and Mail

AstraZeneca's Innovative Cancer Study: A Potential Game-Changer?

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca's ongoing study, titled 'A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)', aims to evaluate the safety and effectiveness of AZD9574, alone and with other anti-cancer drugs, in patients with advanced cancers. The study tests AZD9574, an experimental drug, both as a standalone treatment and in combination with other drugs like Temozolomide, Trastuzumab Deruxtecan, and Datopotamab Deruxtecan. These interventions target various advanced solid tumors, including breast, ovarian, pancreatic, and prostate cancers. This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused. The study is designed to escalate doses to determine safety and efficacy. Key dates for the study include its start on June 24, 2022, with the latest update submitted on July 23, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates for stakeholders. The study's progress could influence AstraZeneca's stock performance and investor sentiment, especially if the results show promising efficacy. As the study involves novel cancer treatments, it could impact the competitive landscape in oncology, potentially affecting other companies in the sector. The study is currently recruiting, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store